amifostine anhydrous has been researched along with cardiovascular agents in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phillips, KA; Tannock, IF | 1 |
| Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP | 1 |
| Antoniou, J; Chalifour, LE; Ciobanu, I; Demers, CN; Héon, S; Mwale, F; Servant, N | 1 |
| Bjelogrlic, SK; Jokanovic, M; Jovic, V; Radic, J; Radulovic, S | 1 |
1 review(s) available for amifostine anhydrous and cardiovascular agents
| Article | Year |
|---|---|
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Topics: Amifostine; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Leukopoiesis; Randomized Controlled Trials as Topic; Razoxane; Research Design; Thrombocytopenia | 1998 |
3 other study(ies) available for amifostine anhydrous and cardiovascular agents
| Article | Year |
|---|---|
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 1999 |
Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Bone Density; Bone Resorption; Cardiovascular Agents; Doxorubicin; Drug Therapy, Combination; Female; Femur; Lumbar Vertebrae; Radiation-Protective Agents; Rats; Razoxane; Tomography, X-Ray Computed | 2005 |
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Creatine Kinase; Doxorubicin; Female; Hydroxybutyrate Dehydrogenase; Mice; Mice, Inbred BALB C; Myocardium; Radiation-Protective Agents; Razoxane; Time Factors | 2007 |